Meta-analysis · J Cardiovasc Pharmacol Ther 2020
PCSK9/ezetimibe diabetes meta-analysis
Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Ezetimibe on Risk of New-Onset Diabetes: A Systematic Review and Meta-Analysis of Large, Double-Blinded Randomized Controlled Trials.
The bottom line
Neither PCSK9 inhibitors nor ezetimibe increase the risk of new-onset diabetes when added to guideline-directed medical therapy.
No excess riskUS status: Not applicable
At a glance
- Medicine
- PCSK9 inhibitors (PCSK9i) or ezetimibe
- Compared with
- Placebo/control added to guideline-directed medical therapy
- People
- 72,298
- Who took part
- Patients without previously diagnosed diabetes from large, double-blinded RCTs of PCSK9 inhibitors (8 trials) or ezetimibe (3 trials), with at least 100 patients per treatment arm and follow-up of at least 52 weeks
- Design
- Systematic review and meta-analysis of double-blinded randomized controlled trials, random effects model
- Follow-up
- At least 52 weeks
- Main question
- Number of incident (new-onset) diabetes cases
Main result
PCSK9i: risk ratio [RR] = 0.99, P = .87, 95% CI = 0.92-1.07; Ezetimibe: RR = 1.05, P = .37, 95% CI = 0.95-1.15
In the trial's own words
“Participants randomized to PCSK9i did not differ from the control patients in diabetes incidence (risk ratio [RR] = 0.99, P = .87, 95% CI = 0.92-1.07). Participants randomized to ezetimibe did not differ from the control patients in diabetes incidence (RR = 1.05, P = .37, 95% CI = 0.95-1.15).”
Quoted from the abstract of J Cardiovasc Pharmacol Ther 2020, checked word for word against PubMed. PubMed 32419478 · Full paper (DOI)
Common questions
What did the PCSK9/ezetimibe diabetes meta-analysis trial find?
Neither PCSK9 inhibitors nor ezetimibe increase the risk of new-onset diabetes when added to guideline-directed medical therapy.
Who was in PCSK9/ezetimibe diabetes meta-analysis?
72,298 people. Patients without previously diagnosed diabetes from large, double-blinded RCTs of PCSK9 inhibitors (8 trials) or ezetimibe (3 trials), with at least 100 patients per treatment arm and follow-up of at least 52 weeks.
What was PCSK9/ezetimibe diabetes meta-analysis's main result?
PCSK9i: risk ratio [RR] = 0.99, P = .87, 95% CI = 0.92-1.07; Ezetimibe: RR = 1.05, P = .37, 95% CI = 0.95-1.15
Related trials
- CTT 2019 older people (2019)Statins reduce major vascular events across all age groups including older people, though the evidence for benefit beyond age 75 without pre-existing vascular disease is less direct and being addressed by further trials.
- CTT 2022 muscle (2022)Statins cause a small, mostly mild excess of muscle pain primarily in the first year of treatment, with over 90% of muscle symptom reports in statin users not actually due to the statin, and this risk is far outweighed by cardiovascular benefits.
- CTT 2024 diabetes (2024)Statins cause a modest, dose-dependent increase in new-onset diabetes and worsening glycaemia, driven by small upward shifts in glucose/HbA1c, but this risk is already outweighed by the overall cardiovascular benefit of statin therapy.
- PCSK9 vs statin monotherapy meta-analysis (2026)In patients who cannot tolerate statins, PCSK9 inhibitor monotherapy lowers LDL-C, ApoB, and raises HDL-C more than high-intensity statin monotherapy, though it is less effective at lowering triglycerides.
Get your LDL treated to a goal
Preval Health's protocols follow trials like this one. Licensed clinicians set your goal, prescribe and recheck until you reach it.
Get startedEducation only, not medical advice. Results describe the people in this trial and can differ for you. Talk with your clinician before starting or stopping any medicine. Back to all 106 trials.